摘要
目的总结英夫利西单抗(IFX)治疗克罗恩病(CD)的使用现状。方法选取扬州大学附属医院信息系统(HIS) 2017年9月至2018年8月使用过IFX的10例CD住院患者的临床资料,回顾性分析IFX使用情况,包括适应证、禁忌证、用药前筛查、使用剂量及疗程、药物联用情况、临床疗效及不良反应等。结果 10例CD患者使用IFX均符合适应证要求,且排除禁忌证并完成用药前筛查,按药品说明书给予合适剂量、疗程及联合用药;1例临床症状尚稳定的缓解期患者,因内镜下表现较重,使用IFX治疗后明显好转;1例为缓解期转入医院行进一步维持治疗;其余8例在使用IFX后临床症状明显缓解。1例外院转入为进一步维持治疗CD患者除外,其余9例患者在使用IFX治疗后8周时与治疗前相比,平均Best CDAI评分、C反应蛋白、红细胞沉降率、血小板计数均明显下降,血清白蛋白与血红蛋白均明显升高(P <0. 05);10例CD患者共发生4例次不良反应,包括输液反应和感染。结论 IFX能迅速缓解CD患者的临床症状,治疗有效,需个体化、规律使用,安全性良好。
Objective To summarize the application of infliximab( IFX) in the treatment of Crohn’s disease( CD). Methods The data of ten inpatients treated with IFX from September 2017 to August 2018 were selected from the hospital information system( HIS) in the Affiliated Hospital of Yangzhou University. The application of IFX( indications,contraindications,pre-medication screening,dosage and course of treatment,drug combination therapy,clinical efficacy and adverse reactions) were retrospectively analyzed. Results Ten patients with CD who used IFX met the requirements of indications,the contraindications were excluded and the pre-medication screening was completed. According to the requirements of the drug instructions,the patients were given appropriate dosage,course of treatment and combination of drugs. One patient with stable clinical symptoms in the remission stage showed significant improvement after treatment with IFX because of severe endoscopic manifestations. One patient was transferred to the hospital from other hospital for further maintenance treatment in the remission period. The clinical symptoms of the other 8 patients were relieved obviously after using IFX. Except for one patient with CD transferred to the hospital from other hospital for further maintenance,the average Best CDAI score,C-reactive protein,erythrocyte sedimentation rate and platelet count of the other 9 patients after 8 weeks of IFX treatment were significantly lower than those before treatment,while the levels of serum albumin and hemoglobin were significantly higher than those before treatment( P < 0. 05).There were 4 adverse drug reactions in 10 patients with CD,mainly due to transfusion reaction and infection. Conclusion IFX can rapidly relieve the clinical symptoms of patients with CD,and the treatment is effective and safe. IFX should be used individually and regularly.
作者
王蓓蓓
陈静
黄富宏
WANG Beibei;CHEN Jing;HUANG Fuhong(Department of Pharmacy,The Affiliated Hospital of Yangzhou University,Yangzhou,Jiangsu,China 225001)
出处
《中国药业》
CAS
2019年第21期74-76,共3页
China Pharmaceuticals
基金
江苏省扬州市2018年市级计划-政策引导计划(软科学研究)[YZ2018167]
关键词
克罗恩病
英夫利西单抗
炎症性肠病
抗肿瘤坏死因子
合理用药
Crohn’s disease
infliximab
inflammatory bowel disease
anti-tumor necrosis factor
rational drug use
